In this study, we investigated a novel PSMA ligand called PSMA-TO-1 (“Tumor-Optimized-1”) that was developed for prolonged circulation time and higher tumor uptake (Dr. H.-J. The gene discussed is FOLH1; the disease is neoplasm.